Results 101 to 110 of about 45,933 (222)
Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient
Case Reports in Transplantation, 2018 Drug-induced liver injury (DILI) has not been previously reported as a complication of treatment with everolimus. A 56-year-old Caucasian male liver transplant recipient developed DILI after receiving everolimus.
Serena Patel +3 more
doaj +1 more source
Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies
Medicinal Research Reviews, EarlyView.ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva +23 more
wiley +1 more source
Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC)
, 2010 Rohan Shahani, Kevin G Kwan, Anil KapoorDivision of Urology, Department of Surgery, St. Joseph’s Healthcare Hamilton and McMaster University, Hamilton, Ontario, CanadaAbstract: Renal cell carcinoma (RCC) is one of the most lethal genitourinary ...
Rohan Shahani, Anil Kapoor, Kevin G Kwan
core
Hyperglykemie bij gebruik van everolimus [PDF]
, 2014 BACKGROUND: Everolimus is an orally administered anti-cancer drug that inhibits the mammalian target of rapamycin (mTOR) signal transduction route. Use of everolimus may be associated with insulin resistance, manifesting in impaired glucose tolerance or ...
Schellens, Jan H M +5 more
core
Precision Medical Sciences, EarlyView.Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang +7 more
wiley +1 more source
Everolimus-eluting stents: update on current clinical studies
, 2011 Dominic J Allocco, Anita A Joshi, Keith D DawkinsBoston Scientific Corporation, Natick, MA, USAAbstract: Everolimus-eluting stents (EES) have become the most commonly implanted coronary stents worldwide.
Joshi AA, Allocco DJ, Dawkins KD
core
Asia-Pacific Journal of Clinical Oncology, EarlyView.This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott +8 more
wiley +1 more source
, 2010 Chris CoppinMedical Oncology, BC Cancer Agency and University of British Columbia, Vancouver, CanadaAbstract: Everolimus (RAD001, Afinitor® Novartis) is the first oral inhibitor of mTOR (mammalian target of rapamycin) to reach the oncology clinic.
Chris Coppin
core
The Impact of Common Medications on Male Fertility: An Updated Systematic Review
Andrology, EarlyView.ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli +7 more
wiley +1 more source
Everolimus – a new approach in the treatment of renal cell carcinoma
, 2010 G Anandappa, AE Hollingdale, TG EisenDepartment of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UKAbstract: With the increasing understanding of the biology of the disease and the development of targeted therapy, there has ...
G Anandappa, TG Eisen, AE Hollingdale
core